Difference between revisions of "Vascular sarcoma"
Jump to navigation
Jump to search
m |
|||
Line 37: | Line 37: | ||
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1093/annonc/mds237 Agulnik et al. 2013] |
| style="background-color:#91cf61" |Phase II | | style="background-color:#91cf61" |Phase II | ||
|- | |- | ||
Line 49: | Line 49: | ||
===References=== | ===References=== | ||
− | #Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [ | + | #Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22910841 PubMed] |
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== |
Revision as of 14:33, 7 March 2020
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ejdavis25 |
0 regimens on this page
0 variants on this page
|
- Note: this page contains regimens for several subtypes of vascular sarcoma. The following links will take you to disease-specific pages:
- Regimens for Kaposi sarcoma are here.
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
Angiosarcoma, all lines of therapy
Bevacizumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Agulnik et al. 2013 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. link to original article contains verified protocol PubMed
Paclitaxel monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Penel et al. 2008 (ANGIOTAX) | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive medications
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains verified protocol PubMed